Sanofi and Regeneron hosted a conference call & webcast following the approval of Dupixent® for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease.

The presentation was followed by a Q&A session.

  • Presentation
  • Press Release - March 28, 2017: Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis